Incidence

Chromocell Issues Letter to Stockholders from Chief Executive Officer

Retrieved on: 
Tuesday, April 9, 2024
Erythromelalgia, Consultant, Toxicity, ChromeOS, Abrasion (medical), Letter, Uveitis, Growth, Opioid, Neuropathic pain, Incidence, Physiology, Patient, NAV, Mortality, IPO, Human, Rash, Outline, Lawyer, Annual report, CHRO, PRK, Pain, Glaucoma, NSAID, Therapy, Family, Photorefractive keratectomy, FDA, Liver, Food, Pharmaceutical industry

We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).

Key Points: 
  • We transferred $2.2 million in liabilities to Chromocell Corporation in exchange for 2,600 shares of Series C Convertible Redeemable Preferred Stock (“Series C Preferred Stock”).
  • Our CEO has agreed to further defer a considerable portion of his accrued compensation, affirming the belief in Chromocell’s mission.
  • We truly feel that our IPO and recent therapeutic development activities have positioned Chromocell for long term growth and success.
  • I wish to thank you for your support and remain a resource to each of you as we move forward.

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

Retrieved on: 
Tuesday, April 9, 2024
Plasma, MRI, Neoplasm, Atossa, Ki-67, Associate, RECIST, Magnetic resonance imaging, Incidence, Patient, MD, Woman, AACR, Clinical trial, Therapy, Breast cancer, Safety, Division, Recurrence, Exemestane, Annual general meeting, Medical imaging

SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.

Key Points: 
  • SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • The data, which is being presented at the American Association for Cancer Research (AACR) Annual Meeting, is from the 40mg pharmacokinetic (PK) run-in cohort of the study.
  • At 28 days, six of the seven had Ki-67 levels below 10% and stayed on treatment for an additional five months.

Sustainable Green Team, Ltd.'s (SGTM) Bold Breakthrough, Revolutionizing Agriculture with Organic Pellet Fertilizer and Micro Encapsulation Technology

Retrieved on: 
Monday, April 8, 2024
Health, Farmer, Nutrient, Environment, Agriculture, Incidence, Green Team, Management, Carbon, OTCQX, IP, Water, Immune system, Patent, Intellectual property, Soil

With the agreement, SGTM can create pelletized organic fertilizers for easier handling and distribution.

Key Points: 
  • With the agreement, SGTM can create pelletized organic fertilizers for easier handling and distribution.
  • Additionally, the deal includes a method to encapsulate beneficial microbes, improving their effectiveness in the soil.
  • This combination has the potential to revolutionize agriculture, providing sustainable agricultural solutions and enhancing soil qualities for farmers.
  • The organic fertilizer developed by SGTM has proven to be a game-changer in the field.

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Retrieved on: 
Monday, April 8, 2024
Patient, Cerebrovascular disease, Stroke, Accelerated approval (FDA), European Medicines Agency, Doctor of Philosophy, Osteomalacia, PROMIS, Therapy, Conditional, Natural history, CTX, Pros, ADAS, Risk, DSM-IV codes, Cohort, Aes, Alkaline phosphatase, Rickets, EMA, PXE, Safety, Epilepsy, Clinical trial, Food, Hospital, Disability, BSAP, Cardiovascular disease, Disease, PD, Paresis, Consultant, Hypophosphatemia, Fatigue, Survivor, Sclera, FDA, Observational study, Pyrophosphate, Choroid, Incidence, Retina, Biomarker, Life, Event, Medical imaging

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive topline safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency (PXE, pseudoxanthoma elasticum) and ENPP1 Deficiency.

Key Points: 
  • “We are excited by the excellent safety and preliminary efficacy profile of INZ-701 in adults with ABCC6 Deficiency,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • The patients were assigned to three dose cohorts of INZ-701: 0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=4).
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
Sunday, April 7, 2024
Uric acid, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, Atherosclerosis, FAHA, Cleveland Clinic, Bempedoic acid, Ezetimibe, Therapy, Anemia, Pain, MACE, Sinusitis, ACC, FOMA, FNLA, FACC, Obesity, Cardiovascular disease, Esperion Therapeutics, Abdominal pain, Risk, Gout, Spasm, Woman, American College, Body mass index, ESPR, Back pain, Outcome, ATP, Safety, Fatigue, Arthralgia, ANN, Angioedema, Kidney, Journal, Constipation, University, Adverse event, Pregnancy, CLEAR, Rash, MPH, Rupture, FDA, Molina Healthcare, JACC, Hypersensitivity, Health, Circulatory system, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Dietary supplement

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis

Retrieved on: 
Thursday, April 4, 2024
Sarcoidosis, ANI, Disease, Incidence, Education, Patient, African Americans, Research, FSR, CAC, Inflammation, Human, Granuloma, Pharmaceutical industry

BAUDETTE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) https://www.anipharmaceuticals.com/ (Nasdaq : ANIP) is proud to support the Foundation for Sarcoidosis Research’s (FSR) commitment to sarcoidosis patients and efforts to increase disease awareness during April’s Sarcoidosis Awareness Month.

Key Points: 
  • BAUDETTE, Minn., April 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) https://www.anipharmaceuticals.com/ (Nasdaq : ANIP) is proud to support the Foundation for Sarcoidosis Research’s (FSR) commitment to sarcoidosis patients and efforts to increase disease awareness during April’s Sarcoidosis Awareness Month.
  • During the month of April, members of the ANI organization are raising awareness of sarcoidosis by wearing “Say Sarcoidosis” pins offered through FSRs National Awareness Campaign, “Say Sarcoidosis.” In addition, ANI members will also be wearing purple on April 13th in honor of “World Sarcoidosis Awareness Day.”
    According to the FSR, sarcoidosis is a rare inflammatory disease characterized by the formation of granulomas predominately in the lungs and, to a lesser extent, in other organs of the body.
  • “We applaud the Foundation for Sarcoidosis Research’s Awareness Campaign – “Say Sarcoidosis” and their ongoing education and support of people who live with sarcoidosis.
  • “We are grateful for ANI Pharmaceuticals’ commitment to increasing awareness and education about those living with sarcoidosis,” said Mary McGowan, Chief Executive Officer of the FSR.

Cybercriminals Abuse Remote Desktop Protocol (RDP) in 90% of Attacks Handled by Sophos Incident Response in 2023, Sophos’ Newest Active Adversary Report Finds

Retrieved on: 
Wednesday, April 3, 2024
Organization, Directory, Face, Attack, Incidence, Risk, Active, RDP, Plague, Risk management

OXFORD, United Kingdom, April 03, 2024 (GLOBE NEWSWIRE) --  Sophos, a global leader of innovative security solutions that defeat cyberattacks, today released the Active Adversary analysis, “It’s Oh So Quiet (?): The Sophos Active Adversary Report for 1H 2024.” The report, which analyzes more than 150 incident response (IR) cases handled by the Sophos X-Ops IR team in 2023, found that cybercriminals abused remote desktop protocol (RDP)—a common method for establishing remote access on Windows systems—in 90% of attacks. This was the highest incidence of RDP abuse since Sophos began releasing its Active Adversary reports in 2021, covering data from 2020.

Key Points: 
  • ): The Sophos Active Adversary Report for 1H 2024 .” The report, which analyzes more than 150 incident response (IR) cases handled by the Sophos X-Ops IR team in 2023, found that cybercriminals abused remote desktop protocol (RDP )—a common method for establishing remote access on Windows systems—in 90% of attacks.
  • This was the highest incidence of RDP abuse since Sophos began releasing its Active Adversary reports in 2021, covering data from 2020.
  • The Sophos Active Adversary Report for 1H 2024 is based on more than 150 incident response (IR) investigations spanning the globe across 26 sectors.
  • ): The Sophos Active Adversary Report for 1H 2024 on Sophos.com.

National Study: Ballad Health, ETSU Trauma Consolidation Saves Hundreds of Lives

Retrieved on: 
Monday, April 1, 2024
Trauma center, Level 3, Learning, Survival, Incidence, Partnership, Stunning, Ballad Health, Patient, Trauma, Research, Mortality, Lead, University, Death, Health, Injury, Johnson City Medical Center, Investment, Emergency medical services, Nursing, Patient safety, ICU, ETSU, Trauma Center, Physician, Rehabilitation, Hospital

In terms of lives, the reduction in the rate of deaths equates to hundreds of lives saved due to the successful consolidation of the region’s two Level 1 trauma centers.

Key Points: 
  • In terms of lives, the reduction in the rate of deaths equates to hundreds of lives saved due to the successful consolidation of the region’s two Level 1 trauma centers.
  • It found the patients with the highest likelihood of death due to severity had significantly improved survival rates post-consolidation.
  • Assisted by national experts, the advisory group recommended consolidation of the region’s two Level 1 trauma centers into one at Johnson City Medical Center, while maintaining Level 3 trauma services at Holston Valley Medical Center and Bristol Regional Medical Center.
  • “Excellent trauma care is a team effort from every corner of our region,” said Ballad Health Chairman and CEO Alan Levine.

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 29, 2024
Retina, Chair, Three Months, Biologics license application, Secretome, Disease, Infection, Incidence, Paratriathlon, Inflammation, Patient, Sale, Limbal stem cell, Research, CIRM, Acquisition, Commercial, Eye, Safety, Retinitis pigmentosa, Food, FDA, BLA, Stargardt disease, Physician, Contingency, Protease, Cryptocurrency

ARLINGTON, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • “In 2023, we focused on clinical execution, advancing our Phase 2b CHASE trial of KPI-012 for the treatment of PCED.
  • In December 2023 and March 2024, KALA announced private placement financings with an institutional investor, priced at-the-market under Nasdaq rules.
  • Cash Position: As of December 31, 2023, KALA had cash and cash equivalents of $50.9 million, compared to $56.1 million as of September 30, 2023.
  • Operating Loss: For the quarter ended December 31, 2023, loss from operations was $9.6 million, compared to $10.3 million for the same period in 2022.

Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Thursday, March 28, 2024
Research, HNC, Symantec Endpoint Protection, Head, Type, Manganese, Chronic kidney disease, Incidence, ASN, CKD, New Drug Application, LAPC, Patient, Layoff, CRL, NDA, Cancer, Galera, Workforce, Pancreatic cancer, Clinical trial, Cisplatin, Society, Therapy, GRECO, File, Food, SOM, FDA, PDUFA, Pharmaceutical industry

We are continuing to explore strategic options to maximize value to our shareholders, including a potential development path for avasopasem.

Key Points: 
  • We are continuing to explore strategic options to maximize value to our shareholders, including a potential development path for avasopasem.
  • The Prescription Drug User Fee Act (PDUFA) target date assigned by the FDA for the NDA was August 9, 2023.
  • Research and development expenses were $3.2 million in the fourth quarter of 2023, compared to $8.1 million for the same period in 2022.
  • General and administrative expenses were $2.0 million in the fourth quarter of 2023, compared to $5.0 million for the same period in 2022.